Astrazeneca Plc Stock Price To Earning
| AZN Stock | SEK 1,462 48.50 3.43% |
AstraZeneca PLC fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Stock. The fundamental analysis module provides a way to measure AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AstraZeneca PLC stock.
AstraZeneca |
AstraZeneca PLC Company Price To Earning Analysis
AstraZeneca PLC's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current AstraZeneca PLC Price To Earning | 437.97 X |
Most of AstraZeneca PLC's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, AstraZeneca PLC has a Price To Earning of 437 times. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The price to earning for all Sweden stocks is notably lower than that of the firm.
AstraZeneca Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AstraZeneca PLC's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics of similar companies.AstraZeneca PLC is currently under evaluation in price to earning category among its peers.
AstraZeneca Fundamentals
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 2.49 T | |||
| Shares Outstanding | 1.55 B | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 46.67 % | |||
| Price To Earning | 437.97 X | |||
| Price To Book | 6.15 X | |||
| Price To Sales | 49.17 X | |||
| Revenue | 44.35 B | |||
| Gross Profit | 35.73 B | |||
| EBITDA | 9.33 B | |||
| Net Income | 3.29 B | |||
| Cash And Equivalents | 4.89 B | |||
| Cash Per Share | 3.15 X | |||
| Total Debt | 22.96 B | |||
| Debt To Equity | 0.87 % | |||
| Current Ratio | 0.96 X | |||
| Book Value Per Share | 23.91 X | |||
| Cash Flow From Operations | 9.81 B | |||
| Earnings Per Share | 22.08 X | |||
| Price To Earnings To Growth | 1.36 X | |||
| Target Price | 1636.64 | |||
| Number Of Employees | 37 | |||
| Beta | 0.19 | |||
| Market Capitalization | 2.26 T | |||
| Total Asset | 96.48 B | |||
| Retained Earnings | 8.07 B | |||
| Working Capital | (3.16 B) | |||
| Current Asset | 12.77 B | |||
| Current Liabilities | 15.93 B | |||
| Z Score | 58.8 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 3.03 % | |||
| Net Asset | 96.48 B | |||
| Last Dividend Paid | 2.9 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.